Sutro Biopharma Inc. (STRO) Prices 6M Share Common Offering at $21/Sh

Pre-Open Stock Movers 12/08: (LXRX) (SFIX) (SMAR) Higher; (PEN) (CONN) (MRNS) Lower (more...)

Pre-Open Stock Movers

Lexicon Pharmaceuticals (NASDAQ: LXRX) 38% HIGHER; Citi upgraded from Neutral to Buy with a price target of $6.00 (from $2.10).

Stitch Fix (NASDAQ: SFIX) 37.9% HIGHER; reported Q1 EPS of $0.09, $0.29 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $490.4 million versus the consensus estimate of $481.17 million. Also announced that... More

After-Hours Stock Movers 12/07: (SFIX) (HOLI) (SMAR) Higher; (MRNS) (IBIO) (ARCT) Lower (more...)

After-Hours Stock Movers

Stitch Fix (NASDAQ: SFIX) 37.9% HIGHER; reported Q1 EPS of $0.09, $0.29 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $490.4 million versus the consensus estimate of $481.17 million. Also announced that Dan Jedda has joined the company, reporting to Katrina Lake. Jedda will be appointed CFO effective December 9, 2020. Dan Jedda joins the company from Amazon where he was Vice President and CFO for Digital Video (including Amazon Studios), Digital Music, and the Advertising and Corporate Development organizations.

Hollysys Automation (NASDAQ:... More

Sutro Biopharma (STRO) Announces Proposed Public Offering of 5 Million Shares of Common Stock

Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a proposed underwritten public offering in which it intends to offer and sell 5,000,000... More

Sutro Biopharma Inc. (STRO) Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at ASH

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a poster presentation at the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial for its CD74-targeted antibody drug conjugate (ADC) STRO-001 for patients with late-line Non-Hodgkin Lymphoma (NHL). Additionally, data were presented from preclinical studies conducted in collaboration with researchers from the Fred Hutchinson Cancer Research Center.

"With three product candidates... More